Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...
This was the stock's fourth consecutive day of losses.
Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...
In the last year, many Amgen Inc. (NASDAQ:AMGN) insiders sold a substantial stake in the company which may have sparked ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
FDA Approves Treatment for gMG FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), ...
Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...
The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...
US biotech Amgen (Nasdaq: AMGN) has won approval from the US regulator for Uplizna (inebilizumab-cdon) to treat adults with ...
Amgen receives US FDA approval for Uplizna to treat Adults with generalized myasthenia gravis: Thousand Oaks, California Saturday, December 13, 2025, 11:00 Hrs [IST] Amgen announc ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
TipRanks on MSN
Amgen price target raised to $425 from $381 at HSBC
HSBC raised the firm’s price target on Amgen (AMGN) to $425 from $381 and keeps a Buy rating on the shares as part of a 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback